RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $135

Benzinga Newsdesk www.benzinga.com Negative 94.7%

Neg 94.7% Neu 0% Pos 0%

RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $148 to $135.